Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein. 2022

Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
College of Stomatology/Hospital of Stomatology/Guangxi Key Laboratory of Nanobody Research/Guangxi Nanobody Engineering Research Center/Laboratory Animal Center/School of Basic Medical Sciences/The Second Clinical Medical College, Guangxi Medical University, Nanning 530021, China.

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on global public health. This study screened and yielded specific nanobodies (Nbs) against SARS-CoV-2 spike protein receptor binding domain (RBD), following testing its basic characteristics. A nanobody phage library was established by immunizing a camel with RBD protein. After three rounds of panning, the positive colonies were screened by enzyme-linked immunosorbent assay (ELISA). By sequencing, four different sequences of nanobody gene fragments were selected. The four nanobody fusion proteins were expressed and purified, respectively. The specificity and affinity of the four nanobodies were identified by ELISA. Our results showed that an immune phage display library against SARS-CoV-2 has been successfully constructed with a library capacity of which was 4.7 × 108 CFU. The four purified nanobodies showed specific high-affinity binding SARS-CoV-2 S-RBD. Among these, the antigen binding affinity of Nb61 was more comparable to that of commercial rabbit anti-SARS-CoV-2 S-RBD antibodies. In sum, our study has obtained four nanobody strains against SARS-CoV-2 S-RBD with significant affinity and specificity, therefore laying an essential foundation for further research as well as the applications of diagnostic and therapeutic tools of SARS-CoV-2.

UI MeSH Term Description Entries
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D002162 Camelus Two-toed, hoofed mammals with four legs, a big-lipped snout, and a humped back belonging to the family Camelidae. They are native to North Africa, and Western and Central Asia. Camels,Dromedary,Bactrian Camels,Bractrian Camels,Camelus bactrianus,Camelus dromedarius,Bactrian Camel,Bractrian Camel,Camel,Camel, Bactrian,Camel, Bractrian,Camels, Bactrian,Camels, Bractrian,Dromedaries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody
D061905 Single-Domain Antibodies An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN. Single-Domain Antibody,VHH Antibodies,VHH Antibody,Immunoglobulin VH Domain Fragments,Immunoglobulin VL Domain Fragments,Nanobodies,VH Domain Fragments,VHH Fragments,VHH Immunoglobulin Fragments,VL Domain Fragments,VNAR Fragments,VNAR Immunoglobulin Fragments,Antibody, Single-Domain,Antibody, VHH,Single Domain Antibody
D064370 Spike Glycoprotein, Coronavirus A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion. Spike Glycoprotein, Bovine Coronavirus,Spike Glycoproteins, Coronavirus,E2 Spike Glycoprotein, Coronavirus,Glycoprotein S, Coronavirus,Spike Glycoprotein S1, Coronavirus,Spike Protein S2, Coronavirus,Spike Protein, Coronavirus,Coronavirus Spike Glycoprotein,Coronavirus Spike Protein

Related Publications

Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
December 2021, Virusdisease,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
January 2024, bioRxiv : the preprint server for biology,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
May 2024, eLife,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
November 2021, Computers in biology and medicine,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
September 2022, International journal of molecular sciences,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
December 2021, NPJ vaccines,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
January 2024, International journal of biological macromolecules,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
June 2023, Molecular and cellular biochemistry,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
April 2024, Antiviral research,
Qianling Su, and Wei Shi, and Xianing Huang, and Yakun Wan, and Guanghui Li, and Bengang Xing, and Zhi Ping Xu, and Hongbo Liu, and Bruce D Hammock, and Xiaomei Yang, and Shihua Yin, and Xiaoling Lu
February 2022, Bioorganic chemistry,
Copied contents to your clipboard!